These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22951787)

  • 1. [Focal dystonias and their treatment with dysport (botulinum toxin type A)].
    Orlova OR; Timerbaeva SL; Khat'kova SE; Kotliarov VV; Korenko LA; Zalialova ZA; Fal'kovskiĭ IV; Shperling LP; Antipova LN; Antipenko EA; Mingazova LR; Soĭkher MI; Krasavina DA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):81-9. PubMed ID: 22951787
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin physiology in focal hand and cranial dystonia.
    Karp BI
    Toxins (Basel); 2012 Nov; 4(11):1404-14. PubMed ID: 23202323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias.
    De Bartolo MI; Manzo N; Ferrazzano G; Baione V; Belvisi D; Fabbrini G; Berardelli A; Conte A
    Toxins (Basel); 2020 Apr; 12(5):. PubMed ID: 32344856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Focal or Segmental Dystonia Resistant to Botulinum Toxin: How Do You Treat Patients in Whom Botulinum Toxin Treatment Has No Effect?].
    Nomura T
    Brain Nerve; 2022 May; 74(5):581-587. PubMed ID: 35589651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Craniocervical dystonia: clinical and pathophysiological features.
    Colosimo C; Suppa A; Fabbrini G; Bologna M; Berardelli A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():15-21. PubMed ID: 20590803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin A (Dysport®): in dystonias and focal spasticity.
    Keam SJ; Muir VJ; Deeks ED
    Drugs; 2011 May; 71(8):1043-58. PubMed ID: 21668041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reported benefit and weakness after botulinum toxin in dystonia.
    Kassavetis P; Lungu C; Ehrlich D; Alter K; Karp BI
    Parkinsonism Relat Disord; 2020 Nov; 80():10-11. PubMed ID: 32927341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contributions and limitations for botulinum toxin injections for extrapyramidal diseases].
    Hinault P
    Rev Neurol (Paris); 2000 Dec; 156(12):1171-7. PubMed ID: 11139738
    [No Abstract]   [Full Text] [Related]  

  • 12. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
    Karp BI; Alter K
    Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and side-effects of the botulinum toxin A treatment in patients with focal dystonia].
    Likhachev SA; Rushkevich IuN; Chernukha TN; Veevnik EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(3):27-31. PubMed ID: 19365387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department.
    Tomić A; Vujović B; Svetel M; Misković ND; Petrović I; Pekmezović T; Kostić VS
    Vojnosanit Pregl; 2015 Dec; 72(12):1069-73. PubMed ID: 26898029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Laryngeal dystonia--personal experience with botulin toxin treatment].
    Domzał TM; Tomczykiewicz K
    Neurol Neurochir Pol; 2002; 36(1):173-9. PubMed ID: 12053608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog.
    Meyer-Lindenberg A; Wohlfarth KM; Switzer EN
    Aust Vet J; 2003 Oct; 81(10):612-4. PubMed ID: 15080472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current uses of botulinum toxin A as an adjunct to hand therapy interventions of hand conditions.
    Kalliainen LK; O'Brien VH
    J Hand Ther; 2014; 27(2):85-94; quiz 95. PubMed ID: 24524884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.